Fig 1: MYC activation in lymphoma cells induces the oncogenic HSP90 conformation to sustain metabolic complexes. A, Transcript expression heatmap of MYC, HSP90 (HSP90AB1), and HSP90 metabolic interactome components in MYC-dependent BLs and MYC-independent PMBLs. Canonical MYC target genes are marked with black rectangles and genes from the nucleotide's pathway with yellow rectangles. B, Majority of oncogenic HSP90 metabolic interactome components IMPDH2, CTPS1, and CAD are bound to oncogenic HSP90 in a BL patient sample presenting MYC translocation. HSP90 was used as positive control and CLPP as negative control. Chemically inert beads were used as control beads. C, Abundance of the oncogenic HSP90 conformation (higher-order interaction of HSP90 and HSP70 through HOP) in P493–6 BL cells according to MYC induction. Total protein abundance in cells (lysate) and the fraction corresponding to the oncogenic HSP90 conformation purified with PU-H71-beads in P493–6 cells in low MYC and upon its induction by doxycycline (Dc) withdrawal (6 hours). The quantification at the bottom indicates the abundance of the HSP70- and HOP-containing epichaperome complexes (denoted by a green square) normalized to the MYC-low (Dc+) state. D, Representative imaging of IMPDH2-CTPS1 (top) and GPI-RPIA (bottom) endogenous complexes in P493–6 BL cells in lower MYC (0 hours, Dc+) and higher MYC conditions (1, 3, and 6 hours after Dc withdrawal). Bar, 10 µm. Quantification of the IMPDH2-CTPS1 and GPI-RPIA endogenous complexes in P493–6 BL cells in the conditions described. n.s., not significant; ***, P < 0.001.
Fig 2: Intracellular localization of IMPDH2 regulates GTP levels in cell protrusions, RAC1 activity, and cell invasion.a Cells transduced with the indicated constructs (Cl sh control shRNA, IMsh IMPDH2 shRNA, IM-LCK IMPDH2 with LCK membrane-localization domain, IM-GIA IMPDH2 with giantin Golgi localization domain) were separated into the plasma membrane and cytoplasm fractions as described in Methods, followed by immunoblotting with the indicated antibodies Shown are representative images of at least two independent experiments. b Immunofluorescence analysis for IMPDH2 (red) and actin (phalloidin, green), and nuclei (Hoechst, blue) in MDA-MB-231 cells transduced with the indicated constructs. Arrows denote the presence of IMPDH2 at the cell plasma membrane. Scale bar 20 µm. Shown are representative images of two independent experiments. c GTP levels were determined via mass spectroscopy as described in Methods. The data represents average ± SEM of two independent experiments performed in duplicates. Statistics performed by two-tailed unpaired Student’s t-test (****p < 0.0001), exact p value <0.00001 for both cases. d Quantification of GEVAL activity in cell bodies (CB) and cell protrusions (CP) of MDA-MB-231 cells transduced with the indicated constructs and with GEVAL30 or GEVALNull (30 CBs and 30 CPs per cell type). Horizontal bars represent average. Individual values are from two experiments (15 CB and 15CP per experiment). Statistics were performed by a two-tailed unpaired Student’s t-test. e Cells transduced with the indicated constructs were probed in RAC1 activity assay as described in Methods. Shown are representative images of three independent experiments. f Quantification of (e). The data represents the average ± SEM of three independent experiments. Statistics were performed by a two-tailed unpaired Student’s t-test. g Invasion assay of MDA-MB-231 cells transduced with the indicated constructs. The data represents the average ± SEM of three independent experiments performed in duplicates. Statistics were performed by two-tailed unpaired Student’s t-test.
Fig 3: Functional association of the oncogenic HSP90 metabolic interactome and the metabolome in DLBCL. A, Pathways enriched in the oncogenic HSP90 (HSP90onc) interactome from the cytoplasmic fraction of OCI-Ly1 and OCI-Ly7 DLBCL cells. Proteins were identified by HPLC-MS/MS. Pathway enrichment as number of cargoes is indicated by dot size and their relative significance by the adjusted P value as FDR. B, Validation of representative enzymes from the oncogenic HSP90 interactome belonging to the three enriched metabolic pathways (indicated by colored dots) in the DLBCL cell lines OCI-Ly1, OCI-Ly7, Karpas 422, and Toledo. The lanes represent original cytosolic lysates, proteins remaining after oncogenic HSP90 chemical affinity purification (flow-through, FT), oncogenic HSP90 chemical affinity purification (HSP90), and inert chemical affinity purification (control). HSP90 was used as positive control and BLNK was used as non-HSP90-cargo negative control. C, Time course of the abundance of oncogenic HSP90 metabolic interactome components IMPDH2, CTPS1, and CAD upon oncogenic HSP90 inhibition with increasing concentrations of PU-H71 (0.25 and 0.5 µmol/L) or vehicle (0) in OCI-Ly1 cells. HSP70 was used as molecular readout of effective HSP90 inhibition and BLNK as a non-HSP90-cargo negative control. Densitometry of blots are shown at the bottom as color-coded fold changes over vehicle control. D, Association of the oncogenic HSP90 metabolic interactome mapped to RECON (n = 84) with the differentially expressed metabolites upon PU-H71 treatment mapped to RECON (n = 53). Proteins are ordered and color-coded by pathways. Matched protein-metabolite pairs are shown as black rectangles in the association plot. E, Representative images of IMPDH2-CTPS1 and GPI-RPIA endogenous complexes in OCI-Ly1 DLBCL cells exposed to vehicle (Veh) or PU-H71 for 3 and 6 hours. Bar, 10 µm. Quantifications of the PLA signal are shown next to images, with each dot belonging to a single-cell measurement. P values were calculated by t test. ***, P < 0.001.
Fig 4: Delineation of IMPDH2–RAC1 interactions.a Structures of RAC1 (shown in green) in complex with other indicated proteins (shown in blue). The number in parenthesis indicates the corresponding entry in RCSB (Research Collaboratory for Structural Bioinformatics) Protein Data Bank. Note that RAC1 binds to a-helices (shown in red) in the target proteins. b A model of the IMPDH2–RAC1 interaction was created by superimposing the a-helix of IMPDH2 containing K134 (shown in red) onto the analogous helix in the RAC1-Kalirin complex. c Convolved evolutionary coupling of IMPDH2 and RAC1. Strength of the couplings between residues of the two proteins are color-coded with red color denoting the highest probability. Shown in colored frames are regions with a high (green), intermediate (yellow), and low (blue) probability of interactions. d Cells were transduced with control shRNA (Cl sh), IMPDH2 shRNA (IMsh), or IMPDH2 shRNA in combination with wild-type IMPDH2 (IMWT), IMPDH2 lacking 153-225 aa (IM?1), or IMPDH2 lacking 101-134 aa (IM?2). Cells were subjected to immunoprecipitation with the antibodies indicated on the top. The immunoprecipitated materials were probed in immunoblotting with the antibodies indicated on the left. Shown are representative images of at least two independent experiments. e GTP levels were determined via mass spectroscopy as described in Methods. The data represents the average ± SEM of two independent experiments performed in duplicates. Statistics performed by two-tailed unpaired Student’s t-test (****p < 0.0001), exact p value < 0.00001. The data represents the average ± SEM of two independent experiments performed in duplicates. f Cells transduced with the indicated constructs were probed in RAC1 activity assay as described in Methods. Shown are representative images of at three independent experiments. g Quantification of (f). The data represents the average ± SEM of three independent experiments. Statistics were performed by a two-tailed unpaired Student’s t-test.
Fig 5: RAC1 interacts with IMPDH2 and recruits GMPS.a Cells were transduced with the indicated constructs and subjected to immunoprecipitation with the antibodies indicated on the top. The immunoprecipitated materials were probed in immunoblotting with the antibodies indicated on the left. Shown are representative images of at least two independent experiments. b Cells were fixed with ice-cold methanol and separated into cell bodies (CB) or cell protrusions (CP) fractions, followed by immunoblotting with the indicated antibodies. Shown are representative images of two independent experiments. c Proximity ligation assay was performed on sparsely plated cells with the antibodies indicated on the top. Shown are representative images of two independent experiments. d Schematic representation of IMPDH2 deletion mutants. Shown are Bateman domain consisting of two cystathionine-ß-synthase sequences (CBS). e Indicated GST-tagged recombinant IMPDH2 mutants were incubated with recombinant 6xHis-tagged RAC1 (shown on the top), followed by immunoprecipitation with anti-GST tag antibodies and immunoblotting with anti-RAC1 antibodies. Shown are representative images of two independent experiments. f Recombinant full-length IMPDH2 and RAC1 proteins were cross-linked followed by mass spectroscopy as described in Methods. Shown are intra-proteins cross-linked peptides identified with highest confidence. Highlighted in red are cross-linked lysines. Shown are representative gel images of at least two independent experiments.
Supplier Page from Abcam for Anti-IMPDH2 antibody [EPR8365(B)]